OCUL

Ocular Therapeutix Inc

6.97

Oct 30 • 3:59 PM ET -0.34 (-4.65%)

6.95

Aftermarket • 7:52 PM ET -0.02 (-0.29%)

Healthcare Biotechnology USA Small NASD

Peers: EYPT KOD FDMT REGN RGNX OTLK TARS OCGN HROW ABBV

| Held by: VTI IWM VXF IWO PJP VTWO DFAS SCHA XPH IHE

Scroll to Statements

Index	RUT
Market Cap	1.53B
Enterprise Value	1.01B
Income	-301.45M
Sales	52.05M
Book/sh	2.37
Cash/sh	2.73
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	325
IPO	Jul 25, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	29.41
P/B	2.94
P/C	2.56
P/FCF	-
EV/EBITDA	-
EV/Sales	19.43
Quick Ratio	13.03
Current Ratio	13.11
Debt/Eq	0.15
LT Debt/Eq	0.15
Option/Short	Yes / Yes

EPS (ttm)	-1.41
EPS next Y	-1.48
EPS next Q	-0.36
EPS this Y	-5.38%
EPS next Y	1.01%
EPS next 5Y	9.07%
EPS past 3/5Y	-15.40% 11.13%
Sales past 3/5Y	0.29% 24.45%
EPS Y/Y TTM	-10.60%
Sales Y/Y TTM	-8.14%
EPS Q/Q	10.89%
Sales Q/Q	0.12%
Earnings	Aug 03 BMO
EPS/Sales Surpr.	11.50% 2.07%

Insider Own	8.58%
Insider Trans	-0.57%
Inst Own	89.13%
Inst Trans	0.24%
ROA	-53.70%
ROE	-72.99%
ROIC	-50.55%
Gross Margin	87.11%
Oper. Margin	-603.04%
Profit Margin	-579.10%
SMA20	-0.72%
SMA50	-20.90%
SMA200	-23.55%
Trades

Shs Outstand	219.59M
Shs Float	200.76M
Short Float	14.33%
Short Ratio	9.43
Short Interest	28.76M
52W High	16.44 -57.60%
52W Low	6.00 16.17%
Volatility	5.96% 6.39%
ATR (14)	0.47
RSI (14)	42.31
Beta	1.20
Rel Volume	0.86
Avg Volume	3.05M
Volume	2,628,727

Perf Week	7.23%
Perf Month	-4.39%
Perf Quarter	-17.02%
Perf Half Y	-26.09%
Perf YTD	-42.59%
Perf Year	-41.03%
Perf 3Y	182.19%
Perf 5Y	4.97%
Perf 10Y	18.94%
Recom	1.08
Target Price	26.15
Prev Close	7.31
Price	6.97
Change %	-4.65%

Consensus

Strong Buy

Avg. Price Target

$26.15

Implied Upside

+275.2%

Analysts14incl. previous ratings

Rating Distribution13 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 12, 2026	Initiated	UUBS	Buy	$14	+100.9%
Sep 15, 2025	Initiated	CChardan Capital Markets	Buy	$21	+201.3%
Apr 08, 2025	Initiated	WWilliam Blair	Outperform
Mar 18, 2025	Initiated	RRBC Capital Mkts	Outperform	$17	+143.9%
Mar 11, 2025	Initiated	NNeedham	Buy	$15	+115.2%
Oct 16, 2024	Initiated	BScotiabank	Sector Outperform
Jun 20, 2024	Upgrade	TTD Cowen	Hold → Buy	$7 → $11	+57.8%
May 31, 2024	Resumed	PPiper Sandler	Overweight	$15	+115.2%
Feb 09, 2024	Initiated	BBofA Securities	Buy	$15	+115.2%
Apr 21, 2023	Initiated	RRobert W. Baird	Outperform	$18	+158.2%
Aug 10, 2022	Resumed	BBerenberg	Buy	$15	+115.2%
Aug 10, 2021	Upgrade	HH.C. Wainwright	Neutral → Buy	$17	+143.9%
Dec 28, 2020	Downgrade	HH.C. Wainwright	Buy → Neutral
Dec 17, 2020	Initiated	BBerenberg	Buy	$27	+287.4%
Nov 13, 2020	Reiterated	RRaymond James	Strong Buy	$15 → $25	+258.7%
Aug 10, 2020	Reiterated	HH.C. Wainwright	Buy	$10 → $13	+86.5%
Mar 03, 2020	Upgrade	RRaymond James	Outperform → Strong Buy
May 21, 2019	Reiterated	HH.C. Wainwright	Buy	$12 → $9	+29.1%
May 21, 2019	Downgrade	RRaymond James	Strong Buy → Outperform	$11 → $5	-28.3%
May 21, 2019	Downgrade	CCowen	Outperform → Market Perform	$13 → $3	-57.0%

Oct-29-26 07:00AM	Ocular Therapeutix to Participate in November Investor and Scientific Conferences (GlobeNewswire)
Oct-09-26 07:00AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-08-26 10:09AM	Top 4 Healthcare Stocks Backed by Raymond James Analysts (Investing.com)
Oct-04-26 11:09PM	Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus The Weeks Biotech Watchlist (Stocktwits)
Oct-01-26 05:35PM	OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD (Stocktwits)
07:00AM	Loading…
07:00AM	Ocular Therapeutix to Participate in October Scientific and Investor Conferences (GlobeNewswire)
Sep-28-26 01:15PM	OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs (Stocktwits) -20.67%
Sep-18-26 07:00AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-15-26 07:00AM	Ocular Therapeutix Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI in Wet AMD (GlobeNewswire)
Sep-01-26 07:00AM	Ocular Therapeutix to Participate in September and October Investor and Scientific Conferences (GlobeNewswire)
Aug-17-26 07:51PM	OCUL, FDMT Stock Clock Best Day In Weeks After EyePoints Trial Setback Heres Why (Stocktwits) +6.08%
09:19AM	EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback Retail Sees Ocular Therapeutics As A Better Buyout Candidate (Stocktwits)
Aug-13-26 04:05PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-26 04:05PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.15%
Aug-03-26 08:48AM	OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated A Look At Key Highlights (Stocktwits)
07:09AM	Loading…
07:09AM	Ocular Therapeutix: Q2 Earnings Snapshot (Associated Press)
07:00AM	Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
Jul-09-26 04:05PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-26 07:00AM	Ocular Therapeutix to Participate in July Scientific and Investor Conferences (GlobeNewswire)
Jun-22-26 04:05PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.73%
Jun-17-26 12:09PM	OCUL Stock Is Climbing Ahead Of Investor Day What Is On The Agenda? (Stocktwits) +7.83%
08:45AM	Ocular Therapeutix Investor Day to Highlight U.S. FDA Alignment on AXPAXLI NDA with Submission Planned for Fourth Quarter 2026 (GlobeNewswire)
Jun-05-26 07:00AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.25%
Jun-04-26 07:00AM	Ocular Therapeutix to Participate in Clinical Trials at the Summit 2026 (GlobeNewswire) +5.39%
Jun-02-26 07:00AM	Ocular Therapeutix to Host Investor Day on June 17, 2026 (GlobeNewswire) -6.94%
May-15-26 07:00AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-08-26 04:05PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-05-26 07:31AM	Ocular Therapeutix: Q1 Earnings Snapshot (Associated Press)
07:00AM	Ocular Therapeutix Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
Apr-29-26 07:00AM	Ocular Therapeutix Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI in Wet AMD (GlobeNewswire)
07:00AM	Loading…
Apr-28-26 07:00AM	Ocular Therapeutix to Report First Quarter 2026 Financial Results on May 5, 2026 (GlobeNewswire)
Apr-27-26 07:00AM	Ocular Therapeutix to Participate in May Scientific and Investor Conferences (GlobeNewswire)
Apr-22-26 07:00AM	Ocular Therapeutix to Host Investor Day on June 17, 2026 (GlobeNewswire)
Apr-14-26 07:00AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-13-26 07:00AM	Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD (GlobeNewswire)
Apr-01-26 07:00AM	Ocular Therapeutix to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April (GlobeNewswire)
Mar-20-26 06:12PM	EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug (Reuters)
Mar-09-26 04:01PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-26 09:31AM	Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory (Insider Monkey)
Feb-27-26 04:35PM	Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why (StockStory) -6.78% +22.82%
Feb-24-26 07:00AM	Ocular Therapeutix to Participate in March Investor Conferences (GlobeNewswire) +6.48%
03:12AM	Ocular Therapeutix Shares Jump After AXPAXLI Hits SOL-1 Phase 3 Endpoint in Wet AMD (MarketBeat)
Feb-23-26 07:00AM	Ocular Therapeutix to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations (GlobeNewswire) +8.10%
Feb-19-26 06:01PM	Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes (Benzinga) +10.67%
10:41AM	Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses (Newsfile)
Feb-17-26 04:59PM	Ocular Therapeutix Shares Jump 28% as SOL-1 Nears Key Data (GuruFocus.com) -21.28%
09:15AM	Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes (Benzinga)
08:30AM	Ocular Therapeutix stock news: Why positive data led to a 25% drop (Investing.com)
07:00AM	Ocular Therapeutix Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD (GlobeNewswire)
06:07AM	Ocular claims a win with Phase 3 eye drug data even as shares sink (BioPharma Dive)
06:07AM	Ocular claims a win with eye drug data even as shares sink (BioPharma Dive)
05:26AM	Stock Market Today: Dow Futures Gain, Nasdaq Drags-ZIM Integrated Shipping, Masimo, Toll Brothers In Focus (Benzinga)
Feb-13-26 05:00PM	Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 (GlobeNewswire)
Feb-06-26 04:01PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-26 04:06PM	Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates (StockStory)
08:10AM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:12AM	Ocular Therapeutix: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (GlobeNewswire)
Jan-26-26 10:34PM	A Look Back at Pharmaceuticals Stocks' Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack (StockStory) +6.04%
Jan-23-26 04:01PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.64%
Jan-21-26 07:00AM	Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer (GlobeNewswire)
Jan-15-26 04:25PM	Stocks to Watch Thursday: Penumbra, BlackRock, Goldman Sachs (The Wall Street Journal)
04:20PM	Ocular Launches, And Then Yo-Yoes, On Rumors Sanofi Is Preparing A Bigger Bid (Investor's Business Daily)
01:03PM	Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory (Insider Monkey)
10:30AM	Ocular Therapeutix Shares Surge Following Reports Of Stronger Sanofi Bid (Benzinga)
09:47AM	Ocular Therapeutix Launches On Rumors Sanofi Is Preparing A Bigger Bid (Investor's Business Daily)
09:37AM	Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock (The Wall Street Journal)
09:26AM	Strength Seen in Ocular Therapeutix (OCUL): Can Its 6.1% Jump Turn into More Strength? (Zacks)
Jan-13-26 11:04PM	3 Reasons OCUL is Risky and 1 Stock to Buy Instead (StockStory) +6.14%
Jan-02-26 06:07PM	Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales (StockStory)
Dec-31-25 11:25AM	BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD (Insider Monkey)
Dec-11-25 07:44AM	H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission (Insider Monkey)
Dec-09-25 02:23PM	Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application (Insider Monkey)
Dec-08-25 07:00AM	Ocular Therapeutix Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI in Wet AMD (GlobeNewswire) +28.06%
Dec-05-25 07:00AM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 07:00AM	Ocular Therapeutix Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI in NPDR (GlobeNewswire)
Nov-20-25 09:55AM	Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a Bet (Zacks)
Nov-18-25 12:44AM	Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences (Insider Monkey)
Nov-12-25 01:37PM	Ocular Therapeutix Stock Earns 81 RS Rating (Investor's Business Daily)
07:00AM	Ocular Therapeutix to Participate in November and December Investor Conferences (GlobeNewswire)
Nov-10-25 08:16PM	RBC Capital Raises PT on Ocular Therapeutix (OCUL) to $24 Amid Solid Growth Trajectory (Insider Monkey)
Nov-07-25 07:00AM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-25 04:02PM	Ocular Therapeutix Inc (OCUL) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
08:45AM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:43AM	Ocular Therapeutix: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	Ocular Therapeutix Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
07:00AM	Ocular Therapeutix Achieves Target Randomization of 555 Subjects in SOL-R (GlobeNewswire)
Nov-03-25 07:33AM	Ocular Therapeutix Inc (OCUL) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-30-25 09:55AM	Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 82.93%: Here's is How to Trade (Zacks)
Oct-28-25 07:00AM	Ocular Therapeutix to Report Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-24-25 09:55AM	Ocular Therapeutix (OCUL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Oct-17-25 09:54PM	H.C. Wainwright Lifts PT on Ocular Therapeutix (OCUL) to $19 From $15, Keeps a Buy Rating (Insider Monkey)
Oct-08-25 12:57AM	Piper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21 (Insider Monkey)
Oct-07-25 07:00AM	Ocular Therapeutix to Participate in Upcoming Scientific Conferences (GlobeNewswire) +5.01%
Oct-02-25 12:46AM	Ocular Therapeutix (OCUL) Falls Hard on $475-Million Share Sale (Insider Monkey)
Sep-30-25 07:08AM	Ocular Therapeutix Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire) -6.70%
06:21AM	Ocular Therapeutix Investor Day to Highlight Exceptional AXPAXLI Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint (GlobeNewswire)
Sep-24-25 04:06AM	Chardan Capital Initiates Ocular Therapeutix (OCUL) With a Buy Rating (Insider Monkey)
Sep-08-25 07:00AM	Ocular Therapeutix to Host Investor Day on September 30, 2025 (GlobeNewswire) -6.54%
Aug-27-25 07:00AM	Ocular Therapeutix to Participate in September Investor and Scientific Conferences (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderman Todd	Chief Legal Officer	Oct 08 '26	Sale	7.29	11,984	87,363	140,484	Oct 13 05:01 PM
TODD ANDERMAN	Officer	Oct 08 '26	Proposed Sale	7.29	11,984	87,315		Oct 08 04:28 PM
Kaiser Peter	Chief Development Officer	Oct 02 '26	Sale	7.05	9,990	70,430	254,388	Oct 06 04:44 PM
Heier Jeffrey S.	Chief Scientific Officer	Oct 02 '26	Sale	7.05	10,869	76,626	307,457	Oct 06 04:43 PM
PETER KAZUO KAISER	Officer	Oct 02 '26	Proposed Sale	7.05	9,990	70,459		Oct 02 04:08 PM
JEFFREY S. HEIER	Officer	Oct 02 '26	Proposed Sale	7.05	10,869	76,639		Oct 02 04:05 PM
Notman Donald	Chief Operating Officer	Aug 31 '26	Sale	10.24	1,099	11,254	366,529	Sep 02 04:01 PM
DONALD D NOTMAN JR.	Officer	Aug 31 '26	Proposed Sale	10.24	1,099	11,252		Aug 31 04:02 PM
Kaiser Peter	Chief Development Officer	Aug 24 '26	Sale	10.77	3,035	32,687	264,378	Aug 26 05:59 PM
Nayak Sanjay	Chief Strategy Officer	Aug 24 '26	Sale	10.78	1,897	20,450	326,898	Aug 26 05:58 PM
Heier Jeffrey S.	Chief Scientific Officer	Aug 24 '26	Sale	10.78	3,296	35,531	318,326	Aug 26 05:57 PM
Dugel Pravin	See Remarks	Aug 24 '26	Sale	10.77	21,649	233,160	2,525,429	Aug 26 05:56 PM
SANJAY NAYAK	Officer	Aug 24 '26	Proposed Sale	10.78	1,897	20,453		Aug 24 04:45 PM
PRAVIN DUGEL	Officer	Aug 24 '26	Proposed Sale	10.77	21,649	233,186		Aug 24 04:45 PM
JEFFREY S. HEIER	Officer	Aug 24 '26	Proposed Sale	10.78	3,296	35,532		Aug 24 04:44 PM
PETER KAZUO KAISER	Officer	Aug 24 '26	Proposed Sale	10.77	3,035	32,702		Aug 24 04:43 PM
Waheed Nadia	Chief Medical Officer	Jun 03 '26	Sale	8.27	14,828	122,628	300,079	Jun 05 04:01 PM
NADIA K. WAHEED	Officer	Jun 03 '26	Proposed Sale	8.27	14,828	122,648		Jun 03 04:06 PM
Dugel Pravin	See Remarks	May 26 '26	Sale	8.20	21,156	173,479	2,597,170	May 28 04:08 PM
Kaiser Peter	Chief Development Officer	May 26 '26	Sale	8.20	2,967	24,329	266,141	May 28 04:07 PM
Heier Jeffrey S.	Chief Scientific Officer	May 26 '26	Sale	8.20	3,018	24,748	320,350	May 28 04:06 PM
Nayak Sanjay	Chief Strategy Officer	May 26 '26	Sale	8.20	1,858	15,236	328,795	May 28 04:05 PM
SANJAY NAYAK	Officer	May 26 '26	Proposed Sale	8.20	1,858	15,237		May 26 04:30 PM
PETER KAZUO KAISER	Officer	May 26 '26	Proposed Sale	8.20	2,967	24,334		May 26 04:27 PM
JEFFREY S. HEIER	Officer	May 26 '26	Proposed Sale	8.20	3,018	24,745		May 26 04:24 PM
PRAVIN DUGEL	Officer	May 26 '26	Proposed Sale	8.20	21,156	173,513		May 26 04:21 PM
Dugel Pravin	See Remarks	Feb 23 '26	Sale	8.28	20,056	166,064	3,013,022	Feb 25 06:20 PM
Kaiser Peter	Chief Development Officer	Feb 23 '26	Sale	8.28	2,810	23,267	269,108	Feb 25 06:19 PM
Heier Jeffrey S.	Chief Scientific Officer	Feb 23 '26	Sale	8.28	3,057	25,312	323,368	Feb 25 06:18 PM
Nayak Sanjay	Chief Strategy Officer	Feb 23 '26	Sale	8.28	1,759	14,565	330,653	Feb 25 06:17 PM
Waheed Nadia	Chief Medical Officer	Feb 20 '26	Sale	7.74	3,510	27,167	314,907	Feb 24 06:13 PM
LINDSTROM RICHARD L MD	Director	Feb 20 '26	Buy	7.66	60,229	461,354	246,933	Feb 24 06:13 PM
PETER KAZUO KAISER	Officer	Feb 23 '26	Proposed Sale	8.28	2,810	23,268		Feb 23 04:23 PM
PRAVIN DUGEL	Officer	Feb 23 '26	Proposed Sale	8.28	20,056	166,086		Feb 23 04:21 PM
JEFFREY S. HEIER	Officer	Feb 23 '26	Proposed Sale	8.28	3,057	25,298		Feb 23 04:18 PM
SANJAY NAYAK	Officer	Feb 23 '26	Proposed Sale	8.28	1,759	14,563		Feb 23 04:16 PM
NADIA K. WAHEED	Officer	Feb 20 '26	Proposed Sale	7.74	3,510	27,170		Feb 20 04:36 PM
Notman Donald	Chief Operating Officer	Feb 12 '26	Sale	9.04	11,446	103,472	366,356	Feb 17 08:31 PM
Nayak Sanjay	Chief Strategy Officer	Feb 12 '26	Sale	9.04	10,348	93,546	332,412	Feb 17 08:30 PM
Dugel Pravin	See Remarks	Feb 12 '26	Sale	9.04	124,882	1,128,933	3,033,078	Feb 17 08:29 PM
Waheed Nadia	Chief Medical Officer	Feb 12 '26	Sale	9.04	7,863	71,082	318,417	Feb 17 08:28 PM
DONALD D NOTMAN JR.	Officer	Feb 12 '26	Proposed Sale	9.04	11,446	103,481		Feb 12 04:33 PM
PRAVIN DUGEL	Officer	Feb 12 '26	Proposed Sale	9.04	124,882	1,128,584		Feb 12 04:20 PM
STEVE MEYERS	Officer	Feb 12 '26	Proposed Sale	9.04	6,864	62,034		Feb 12 04:18 PM
SANJAY NAYAK	Officer	Feb 12 '26	Proposed Sale	9.04	10,348	93,560		Feb 12 04:16 PM
NADIA K. WAHEED	Officer	Feb 12 '26	Proposed Sale	9.04	7,863	71,082		Feb 12 04:09 PM
Notman Donald	Chief Operating Officer	Feb 04 '26	Sale	8.54	6,035	51,539	377,802	Feb 04 08:23 PM
Notman Donald	Chief Operating Officer	Feb 02 '26	Sale	9.14	5,455	49,859	383,837	Feb 04 08:23 PM
STEVE MEYERS	Officer	Feb 04 '26	Proposed Sale	8.54	4,408	37,636		Feb 04 04:10 PM
DONALD D NOTMAN JR.	Officer	Feb 04 '26	Proposed Sale	8.54	6,035	51,541		Feb 04 04:09 PM
DONALD D NOTMAN JR.	Officer	Feb 02 '26	Proposed Sale	9.14	5,455	49,873		Feb 02 04:29 PM
STEVE MEYERS	Officer	Feb 02 '26	Proposed Sale	9.14	3,052	27,904		Feb 02 04:28 PM
Nayak Sanjay	Chief Strategy Officer	Nov 24 '25	Sale	12.04	1,878	22,611	277,860	Nov 26 04:02 PM
Dugel Pravin	See Remarks	Nov 24 '25	Sale	12.04	19,530	235,141	3,157,960	Nov 26 04:02 PM
Kaiser Peter	Chief Development Officer	Nov 24 '25	Sale	12.02	3,007	36,144	191,433	Nov 26 04:01 PM
Heier Jeffrey S.	Chief Scientific Officer	Nov 24 '25	Sale	12.04	3,469	41,767	245,940	Nov 26 04:01 PM
PRAVIN DUGEL	Officer	Nov 24 '25	Proposed Sale	12.04	19,530	235,083		Nov 24 04:33 PM
SANJAY NAYAK	Officer	Nov 24 '25	Proposed Sale	12.04	1,878	22,616		Nov 24 04:31 PM
PETER KAZUO KAISER	Officer	Nov 24 '25	Proposed Sale	12.02	3,007	36,150		Nov 24 04:30 PM
JEFFREY S. HEIER	Officer	Nov 24 '25	Proposed Sale	12.04	3,469	41,772		Nov 24 04:28 PM
Saroj Namrata	Chief Business Officer	Nov 05 '25	Sale	10.74	25,865	277,790	174,135	Nov 07 04:01 PM
NAMRATA SAROJ	Officer	Nov 05 '25	Proposed Sale	10.74	25,865	277,909		Nov 05 04:20 PM

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Executive ChairmanDr. Pravin U. Dugel M.D.

Chief Operating Officer (Leave of Absence)Mr. Donald Notman Jr.

Chief Commercial OfficerMr. Steve Meyers

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCUL

Ocular Therapeutix Inc

Upgrade your Finviz experience